UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 53

Sortiert nach

Disease-modifying antirheumatic drug prescription patterns in adult rheumatoid arthritis patients in routine clinical practice in Spain

European journal of rheumatology, 2020-10, Vol.7 (4), p.149-157

2020

Volltextzugriff (PDF)

Subcutaneous Tocilizumab Versus Placebo in Combination With Disease‐Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis

Arthritis care & research (2010), 2014-11, Vol.66 (11), p.1653-1661

2014

Volltextzugriff (PDF)

MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study

Annals of the rheumatic diseases, 2016-01, Vol.75 (1), p.170-177

2016

Volltextzugriff (PDF)

Sustained remission of pediatric relapsing polychondritis with adalimumab

Journal of clinical rheumatology, 2014-01, Vol.20 (1), p.45

2014

Volltextzugriff (PDF)

DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists

BMC musculoskeletal disorders, 2009-07, Vol.10 (1), p.91-91, Article 91

2009

Volltextzugriff (PDF)

Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial

American journal of ophthalmology, 2018-11, Vol.195, p.181-190

2018

Volltextzugriff (PDF)

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

The New England journal of medicine, 2014-06, Vol.370 (25), p.2377-2386

2014

Volltextzugriff (PDF)

SP070KIDNEY BIOPSY FINDINGS IN PATIENTS WITH PRIMARY SJÖGREN SYNDROME

Nephrology, dialysis, transplantation, 2017-05, Vol.32 (suppl_3), p.iii127-iii127

2017

Volltextzugriff (PDF)

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

Annals of the rheumatic diseases, 2013-01, Vol.72 (1), p.43-50

2013

Volltextzugriff (PDF)

Physical function and health‐related quality of life of Spanish patients with ankylosing spondylitis

Arthritis and rheumatism, 2003-08, Vol.49 (4), p.483-487

2003

Volltextzugriff (PDF)

Safety and Efficacy of the Newer Biological Therapeutics in the Treatment of Rheumatoid Arthritis

Clinical Medicine Insights: Therapeutics, 2011-01, Vol.2011 (3), p.195

2011

Volltextzugriff (PDF)

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

The New England journal of medicine, 2012-08, Vol.367 (6), p.508-519

2012

Volltextzugriff (PDF)

Evaluación económica de la monoterapia con tocilizumab frente a adalimumab en artritis reumatoide

Revista española de salud pública, 2013, Vol.87 (4), p.343-350

2013

Volltextzugriff (PDF)

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

The Lancet (British edition), 2009-07, Vol.374 (9685), p.210-221

2009

Volltextzugriff (PDF)

Viscosupplementation for osteoarthritis of the knee

Annals of internal medicine, 2013-01, Vol.158 (1), p.74

2013

Volltextzugriff (PDF)

Assessing utility values in rheumatoid arthritis: A comparison between time trade‐off and the EuroQol

Arthritis and rheumatism, 2006-10, Vol.55 (5), p.751-756

2006

Volltextzugriff (PDF)

Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double‐Blind Withdrawal Study

Arthritis & rheumatology (Hoboken, N.J.), 2021-09, Vol.73 (9), p.1663-1672

2021

Volltextzugriff (PDF)

Abatacept Use in Rheumatoid Arthritis: Evidence Review and Recommendations

Reumatología clinica (Barcelona), 2013-01, Vol.9 (1), p.5-17

2013

Volltextzugriff (PDF)

Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease

Clinical rheumatology, 2011-07, Vol.30 (7), p.993-996

2011

Volltextzugriff (PDF)

Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis

Journal of rheumatology, 2018-04, Vol.45 (4), p.456

2018

Volltextzugriff (PDF)

Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis

Arthritis research & therapy, 2016-11, Vol.18 (1), p.259-259, Article 259

2016

Volltextzugriff (PDF)

Fibromyalgia prevalence and related factors in a large registry of patients with systemic lupus erythematosus

Clinical and experimental rheumatology, 2016-03, Vol.34 (2 Suppl 96), p.S40

2016

Volltextzugriff (PDF)

Dose escalation of the anti-TNF-α agents in patients with rheumatoid arthritis. A systematic review

Rheumatology (Oxford, England), 2007-03, Vol.46 (3), p.529-532

2007

Volltextzugriff (PDF)

1 – 25 von 53

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(53)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(39)
Life Sciences & Biomedicine
(37)
Humans
(35)
Rheumatology
(33)
Female
(28)
Male
(28)
Middle Aged
(27)
Adult
(25)
Rheumatoid Arthritis
(21)
Arthritis, Rheumatoid - Drug Therapy
(18)
Treatment Outcome
(14)
Antirheumatic Agents - Therapeutic Use
(13)
Tumor Necrosis Factor-Alpha - Antagonists & Inhibitors
(12)
Adalimumab
(11)
Aged
(10)
Severity Of Illness Index
(10)
Biological And Medical Sciences
(9)
Diseases Of The Osteoarticular System
(9)
Double-Blind Method
(9)
Drug Therapy
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Disease-modifying antirheumatic drug prescription patterns in adult rheumatoid arthritis patients in routine clinical practice in Spain

Subcutaneous Tocilizumab Versus Placebo in Combination With Disease‐Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis

MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study

Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept

Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis

Sustained remission of pediatric relapsing polychondritis with adalimumab

DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists

Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

SP070KIDNEY BIOPSY FINDINGS IN PATIENTS WITH PRIMARY SJÖGREN SYNDROME

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

Physical function and health‐related quality of life of Spanish patients with ankylosing spondylitis

Safety and Efficacy of the Newer Biological Therapeutics in the Treatment of Rheumatoid Arthritis

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

Evaluación económica de la monoterapia con tocilizumab frente a adalimumab en artritis reumatoide

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

Viscosupplementation for osteoarthritis of the knee

Assessing utility values in rheumatoid arthritis: A comparison between time trade‐off and the EuroQol

Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double‐Blind Withdrawal Study

Abatacept Use in Rheumatoid Arthritis: Evidence Review and Recommendations

Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease

Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis

Fibromyalgia prevalence and related factors in a large registry of patients with systemic lupus erythematosus

Dose escalation of the anti-TNF-α agents in patients with rheumatoid arthritis. A systematic review

Suchergebnisse filtern